GBA1 and Parkinson disease: Given that there is reduction of glucosylceramidase activity in brain tissue from patients with Parkinson’s disease and those with Lewy body dementia, with and without GBA mutations, there is clearly an urgent need to understand how reduced glucosylceramidase activity causes neurodegeneration to facilitate development of new treatments.